The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58
Mosenzon O, Wiviott SD, Heerspink HJL, et al.
Diabetes Care Pub. online 07 July 2021.
Leggi
Breaking news
Characteristics of children diagnosed with type 1 diabetes before vs after 6 years of age in the TEDDY cohort study
Krischer JP, Liu X, Lernmark, Å, et al.
Diabetologia. Pub. online 22 July 2021
Leggi
Continuous glucose monitoring improves glycemic outcomes in children with type 1 diabetes: real-world data from a population-based clinic
Sanderson EE, Abraham MB, Smith GJ, et al.
Diabetes Care. Pub. online 19 July 2021.
Leggi
Development of a life expectancy table for individuals with type 1 diabetes
Tran-Duy A, Knight J, Clarke PM, et al.
Diabetologia. Pub. online 26 July 2021
Leggi
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown E, Heerspink HJL, Cuthbertson DJ, et al.
Lancet. 2021;398(10296):262-276
Leggi
Echocardiographic predictors of long‐term adverse cardiovascular outcomes in participants with and without diabetes mellitus: A follow‐up analysis of the Copenhagen City Heart Study
Özbek BT, Modin D, Møgelvang R, et al.
Diabet Med. Pub. online 12 July 2021
Leggi
A guideline for the outpatient management of glycaemic control in people with cancer
Joharatnam-Hogan N, Chambers P, Dhatariya K, et al.
Diabet Med. 2021;e14636.
Leggi
Usefulness of glucagon-like peptide-1 receptor agonists to reduce adverse cardiovascular disease events in patients with type 2 diabetes mellitus
Grewal S, Zaman N, Borgatta L, et al.
Am J Cardiol. 2021;S0002-9149(21)00522-1.
Leggi
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes
Frías JP, Davies MJ, Rosenstock J, et al.
N Engl J Med. Pub. online 25 June 2021.
Leggi
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein HC, Sattar N, Rosenstock J, et al.
NEJM. Pub. online 28 June 2021.
Leggi